Publicaciones en las que colabora con MARÍA DOLORES CABALLERO BARRIGÓN (29)

2015

  1. Incidence and risk factors for life-threatening bleeding after allogeneic stem cell transplant

    British Journal of Haematology, Vol. 169, Núm. 5, pp. 719-725

  2. Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodisplastic syndrome

    Leukemia Research, Vol. 39, Núm. 8, pp. 828-834

2014

  1. Late differentiation syndrome in acute promyelocytic leukemia: A challenging diagnosis

    Hematology Reports, Vol. 6, Núm. 4, pp. 75-77

  2. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus

    Bone Marrow Transplantation, Vol. 49, Núm. 5, pp. 684-690

  3. Sequential Third-Party Mesenchymal Stromal Cell Therapy for Refractory Acute Graft-versus-Host Disease

    Biology of Blood and Marrow Transplantation, Vol. 20, Núm. 10, pp. 1580-1585

2012

  1. Allogeneic mesenchymal stem cell therapy for refractory cytopenias after hematopoietic stem cell transplantation

    Transfusion, Vol. 52, Núm. 5, pp. 1086-1091

2011

  1. Effect of vitamin D treatment in chronic GVHD

    Bone Marrow Transplantation

2010

  1. Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant

    American Journal of Hematology, Vol. 85, Núm. 4, pp. 290-293

2009

  1. Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Chronic Graft-versus-Host Disease

    Biology of Blood and Marrow Transplantation, Vol. 15, Núm. 10, pp. 1331-1336

2008

  1. Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health Scale Plus the Type of Onset Can Predict Survival Rates and the Duration of Immunosuppressive Therapy

    Biology of Blood and Marrow Transplantation, Vol. 14, Núm. 10, pp. 1163-1171

2006

  1. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients [14]

    Leukemia

  2. Vincristine is an effective therapeutic approach for transplantation-associated thrombotic microangiopathy [5]

    Bone Marrow Transplantation

2005

  1. Effect of pre-transplant cumulative doses of chemotherapeutic drugs on early and long-term hematological recovery after autologous bone-marrow transplantation for lymphoma

    Haematologica, Vol. 90, Núm. 1, pp. 78-85

  2. Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning

    Biology of Blood and Marrow Transplantation, Vol. 11, Núm. 6, pp. 437-447

2004

  1. Antibiotic prophylaxis with meropenem after allogeneic stem cell transplantation

    Bone Marrow Transplantation, Vol. 33, Núm. 2, pp. 183-187

  2. Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: A single-centre sequential-cohort study

    Bone Marrow Transplantation, Vol. 34, Núm. 8, pp. 675-682

2003

  1. Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation

    Blood, Vol. 102, Núm. 3, pp. 1108-1113

2002

  1. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation

    Leukemia, Vol. 16, Núm. 8, pp. 1423-1431

2001

  1. Cidofovir treatment of human polyomavirus-associated acute haemorrhagic cystitis

    Transplant Infectious Disease, Vol. 3, Núm. 1, pp. 44-46

2000

  1. Allogeneic peripheral blood cell transplantation for hypereosinophilic syndrome with myelofibrosis

    Bone Marrow Transplantation, Vol. 25, Núm. 2, pp. 217-218